Prospective analysis of a TRD cohort over a 1-year follow-up with standard of care in Mexico: results for depression severity, treatment response, disability and QoL from the multicenter, observational TRAL Study

Authors

  • Javier Zambrano Consultorio privado https://orcid.org/0009-0005-3576-4435
  • Juan Luis Vázquez Hernández Médico psiquiatra - Hospital Aranda de la Parra - León, Guanajuato, Mexico https://orcid.org/0000-0003-4522-6946
  • Francisco Fernando Brandi Rigal Centro de Salud Brandi Rigal S.C. – Monterrey, Mexico
  • Luis Daniel Alviso de la Serna Avalon Salud, Vinculacion Medica en Salud Mental - Ciudad de México, Mexico https://orcid.org/0000-0001-8266-5409
  • Gabriela Kanevsky Janssen, Pharmaceutical Companies, Argentina
  • Sergio Perocco At the time of this research, SP was an employee at Janssen Pharmaceutical

Keywords:

Mexico, Clinical Outcomes, Treatment-Resistant Depressive Disorder, response, Patient-reported outcomes

Abstract

Introduction: Based on TRAL Mexico subsample, clinical outcomes and Patient-Reported Outcomes (PROs) are reported here. Methods: From 697 patients with MDD recruited from 14 Mexican sites, 140 patients with diagnosis of TRD under standard of care (SOC) were included in the 1-year follow-up. Patients with relevant psychiatric comorbidities or active participation in a clinical trial were excluded. Outcomes were obtained from PROs and clinical assessment scales. Results: Patients were mostly female (82.6%), with a mean age of 47.6 years. Only 44.3% of the patients achieved a clinical response, and remission was around 37% (measured through MADRS). Results from PHQ-9, EQ-5D and SDS show significant symptoms and disability for TRD patients in their everyday life after 1-year of follow-up with SOC. Discussion: TRD patients showed a significant burden of the disease, as current SOC fails to deliver clinically meaningful results for the majority of the patients. Response, remission and relapse are far from the desired outcomes Conclusion: Mexico has undertaken relevant and meaningful strategies to improve mental health resources availability, but some unmet needs are yet to be addressed. All involved stakeholders should consider public policies to enhance clinical outcomes and availability of resources.

 

 

Author Biographies

Javier Zambrano, Consultorio privado

 

 

 

Juan Luis Vázquez Hernández, Médico psiquiatra - Hospital Aranda de la Parra - León, Guanajuato, Mexico

 

 

Francisco Fernando Brandi Rigal, Centro de Salud Brandi Rigal S.C. – Monterrey, Mexico

 

 

Luis Daniel Alviso de la Serna, Avalon Salud, Vinculacion Medica en Salud Mental - Ciudad de México, Mexico

 

 

Gabriela Kanevsky, Janssen, Pharmaceutical Companies, Argentina

 

 

Sergio Perocco, At the time of this research, SP was an employee at Janssen Pharmaceutical

 

 

References

Malhi GS, Mann JJ. Depression. The Lancet. 2018 Nov;392(10161):2299–312.

Storeng SH, Sund ER, Krokstad S. Factors associated with basic and instrumental activities of daily living in elderly participants of a population-based survey: The Nord-Trøndelag Health Study, Norway. BMJ Open. 2018;8(3):1–10.

Xie H, Chen PW, Zhao L, Sun X, Jia XJ. Relationship between activities of daily living and depression among older adults and the quality of life of family caregivers. Frontiers of Nursing. 2018;5(2):97–104.

Kessler RC, Bromet EJ. The Epidemiology of Depression Across Cultures. Annu Rev Public Health. 2013 Mar 18;34(1):119–38.

Conway CR, George MS, Sackeim HA. Toward an evidence-based, operational definition of treatment-resistant depression: When Enough is enough. JAMA Psychiatry. 2017;74(1):9–10.

Mrazek DA, Hornberger JC, Altar CA, Degtiar I. A Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996–2013. Psychiatric Services. 2014;65(8):977–87.

Hasin DS, Sarvet AL, Meyers JL, Saha TD, Ruan WJ, Stohl M, et al. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry. 2018;75(4):336–46.

Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ. What Did STAR*D Teach Us? Results From a Large-Scale, Practical, Clinical Trial for Patients With Depression. Psychiatric Services. 2009 Nov;60(11):1439–45.

Thase M, Connolly R. Unipolar depression in adults: Choosing treatment for resistant depression - UpToDate [Internet]. UpToDate. 2019 [cited 2019 Aug 14]. Available from: https://www.uptodate.com/contents/unipolar-depression-in-adults-choosing-treatment-for-resistant-depression#H925759895

Kraus C, Kadriu B, Lanzenberger R, Zarate CA, Kasper S. Prognosis and improved outcomes in major depression: a review. Transl Psychiatry. 2019;9(1).

O’Reardon JP, Cristancho P, Peshek AD. Vagus Nerve Stimulation (VNS) and Treatment of Depression: To the Brainstem and Beyond. Psychiatry (Edgmont). 2006 May;3(5):54–63.

Döme P, Kunovszki P, Takács P, Fehér L, Balázs T, Dede K, et al. Clinical characteristics of treatment-resistant depression in adults in Hungary: Real-world evidence from a 7-year-long retrospective data analysis. PLoS One. 2021;16(1 January):1–20.

Ionescu DF, Rosenbaum J, Alpert J. Pharmacological approaches to the challenge of treatment-resistant depression. Dialogues Clin Neurosci. 2015;17(2):111–26.

Fedgchin M, Trivedi M, Daly EJ, Melkote R, Lane R, Lim P, et al. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). International Journal of Neuropsychopharmacology. 2019;

Johnston KM, Powell LC, Anderson IM, Szabo S, Cline S. The burden of treatment-resistant depression: A systematic review of the economic and quality of life literature. J Affect Disord. 2019;242(June):195–210.

Lepine BA, Moreno RA, Campos RN, Couttolenc BF. Treatment-resistant depression increases health costs and resource utilization. Revista Brasileira de Psiquiatria. 2012 Dec;34(4):379–88.

Chow W, Doane MJ, Sheehan ; Jack, Alphs L, Le H. Economic Burden Among Patients With Major Depressive Disorder: An Analysis of Healthcare Resource Use, Work Productivity, and Direct and Indirect Costs by Depression Severity. Am J Manag Care. 2019;

Jaffe DH, Rive B, Denee TR. The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study. BMC Psychiatry. 2019;19(1):1–11.

Dibernardo A, Lin X, Zhang Q, Xiang J, Lu L, Jamieson C, et al. Humanistic outcomes in treatment resistant depression: A secondary analysis of the STAR∗D study. BMC Psychiatry. 2018;18(1):1–8.

Caldieraro MA, Tung TC, Agudelo Baena LM, Vilapriño Duprat M, Corral RM, Alviso de la Serna LD, et al. Depression and suicidality severity among TRD patients after 1-year under standard of care: Findings from the TRAL study, a multicenter, multinational, observational study in Latin America. Rev Psiquiatr Salud Ment. 2022;

Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry. 1979;134(4):382–9.

Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–13.

Spitzer RL, Kroenke K, Williams JBW. Validation and utility of a self-report version of PRIME-MD: The PHQ Primary Care Study. J Am Med Assoc. 1999 Nov;282(18):1737–44.

Sheehan KH, Sheehan D V. Assessing treatment effects in clinical trials with the Discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol. 2008;23(2):70–83.

Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research. 2011;20(10):1727–36.

van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets. Value in Health. 2012 Jul;15(5):708–15.

Vázquez Hernández JL, Alviso de la Serna LD, Cruz C, Becerra Palars C, Ibarreche Beltran J, Kanevsky G, et al. Prevalence of Treatment Resistant Depression: TRAL study sub analysis in a Mexican sample | [Internet]. Archivos de Neurociencias. 2023 [cited 2023 Jun 19]. Available from: https://archivosdeneurociencias.org/index.php/ADN/article/view/448

Amos TB, Tandon N, Lefebvre P, Pilon D, Kamstra RL, Pivneva I, et al. Direct and indirect cost burden and change of employment status in treatment-resistant depression: A matched-cohort study using a us commercial claims database. Journal of Clinical Psychiatry. 2018;79(2).

Fujii RK, Goren A, Annunziata K, Mould-Quevedo J. Prevalence, Awareness, Treatment, and Burden of Major Depressive Disorder: Estimates from the National Health and Wellness Survey in Brazil. Value Health Reg Issues. 2012;1(2):235–43.

Moffitt TE, Harrington H, Caspi A, Kim-Cohen J, Goldberg D, Gregory AM, et al. Depression and Generalized Anxiety Disorder. Arch Gen Psychiatry. 2007;64(6):651.

Groen RN, Ryan O, Wigman JTW, Riese H, Penninx BWJH, Giltay EJ, et al. Comorbidity between depression and anxiety: Assessing the role of bridge mental states in dynamic psychological networks. BMC Med. 2020;18(1):1–17.

Guerra M, Ferri CP, Sosa AL, Salas A, Gaona C, Gonzales V, et al. Late-life depression in Peru, Mexico and Venezuela: The 10/66 population-based study. British Journal of Psychiatry. 2009;195(6):510–5.

Borges G, Benjet C, Medina-Mora ME, Orozco R, Wang PS. Treatment of mental disorders for adolescents in Mexico City. Bull World Health Organ. 2008;86(10):757–64.

Pimentel L. The Importance of Mental Health in the Mexican Public Health System. Mexican Journal of Medical Research ICSA. 2019;7(13):1–6.

Martinez W, Galván J, Saavedra N, Berenzon S. Barriers to integrating mental health services in community-based primary care settings in Mexico city: A qualitative analysis. Psychiatric Services. 2017;68(5):497–502.

Alvarez-Monjaras M, Gonzalez D. Depression : Stigma and its. 2016;(November).

Picco L, Subramaniam M, Abdin E, Ajit Vaingankar J, Chong SA. Gender differences in major depressive disorder: findings from the Singapore Mental Health Study. Singapore Med J. 2017;58(11):649–55.

Albert PR. Why is depression more prevalent in women? Journal of Psychiatry and Neuroscience. 2015;40(4):219–21.

Additional Files

Published

2023-10-10

How to Cite

Zambrano, J., Vázquez Hernández, J. L., Brandi Rigal, F. F., Alviso de la Serna, L. D., Kanevsky, G., & Perocco, S. (2023). Prospective analysis of a TRD cohort over a 1-year follow-up with standard of care in Mexico: results for depression severity, treatment response, disability and QoL from the multicenter, observational TRAL Study. Archivos De Neurociencias, 1(Inpress). Retrieved from https://archivosdeneurociencias.org/index.php/ADN/article/view/634

Issue

Articles in press

Section

Original Articles

License

Copyright (c) 2022 Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

September 2022-present © Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez. Open access articles under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) license, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. No commercial re-use is allowed.

January-September 2022 © The authors. Open access articles under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) license, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. No commercial re-use is allowed.

January 2014-December 2021 © Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez. Open access articles under the terms of the Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Most read articles by the same author(s)